There have been significant advances in treating cancer, but patients often succumb to their disease. Innovative approaches remain necessary, and our solution is to attack cancer in new and innovative ways by leveraging novel biology.

VBL is harnessing novel biology in innovative ways, through cutting edge therapies, for unmet medical needs in cancer and chronic immune-inflammatory diseases. Our product pipeline is led by VB-111, a first-in-class anti-cancer gene therapy with a dual mechanism of action, that is in clinical development to treat a wide range of solid tumors.

In addition, VBL has developed two innovative programs that are based on our novel biological findings related to an exciting new, highly specific protein called MOSPD2. Our finding unrevealed the role of MOSPD2 in controlling directed cell movement of immune and tumor cells. We are developing a proprietary monoclonal antibody, VB-601, targeting MOSPD2 for immune inflammatory diseases, as well as bi-specific antibody for cancer, VB-611.

VBL has also developed Lecinoxoids, which are a novel class of investigational orally available anti-inflammatory small molecules that mimic the structure of native phospholipid molecules that regulate the inflammatory process. VBL is developing VB-201, which has demonstrated clinical proof-of-concept in a Phase 2 trial in vascular inflammation and is being evaluated as a treatment for severe COVID-19.